PedAM
Pediatric Disease Annotations & Medicines
| Disease | proteinuria |
| Phenotype | C0022661|chronic kidney disease |
| Sentences | 35 |
| PubMedID- 24867154 | Assessment of proteinuria in patients with chronic kidney disease stage 3: albuminuria and non-albumin proteinuria. |
| PubMedID- 24965167 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. |
| PubMedID- 21849801 | Background/aims: proteinuria is associated with cardiovascular and chronic kidney disease. |
| PubMedID- 26325557 | Importance: steroidal mineralocorticoid receptor antagonists, when added to a renin-angiotensin system blocker, further reduce proteinuria in patients with chronic kidney disease but may be underused because of a high risk of adverse events. |
| PubMedID- 24384547 | Olmesartan is more effective than other angiotensin receptor antagonists in reducing proteinuria in patients with chronic kidney disease other than diabetic nephropathy. |
| PubMedID- 23326865 | In this exploratory short-term study, we demonstrated that treatment with a renin inhibitor, aliskiren, significantly reduced proteinuria in patients with nondiabetic chronic kidney diseases. |
| PubMedID- 26151753 | However, the effects of statins on renal outcomes, including decline in estimated glomerular filtration rate (egfr) and proteinuria in patients with chronic kidney disease (ckd), are controversial. |
| PubMedID- 26528285 | Supplementation with vitamin d in the general population has shown fracture prevention, suggested benefit in cardiovascular health, colorectal cancer prevention and reduction of proteinuria in patients with chronic kidney disease (20, 21). |
| PubMedID- 22917002 | By studying 189 non diabetic ckd patients, the present study clearly shows that aliskiren reduced proteinuria in patients with non-dm chronic kidney disease who were receiving arbs. |
| PubMedID- 22333173 | [the efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease]. |
| PubMedID- 25159718 | In children with prior chronic kidney disease due to idiopathic fsgs, proteinuria should be assessed daily during the first month after transplantation to enable early diagnosis of recurrence. |
| PubMedID- 21150213 | Whereas most chronic kidney disease patients with proteinuria would often require antiproteinuric agents, there are some exceptions. |
| PubMedID- PMC3991017 | More importantly, spironolactone has been reported to further decrease proteinuria in patients with chronic kidney disease already on chronic treatment with ace inhibitors suggesting that aldosterone antagonists may also add to the renoprotective effect of raas inhibition in humans [2,6,7,8]. |
| PubMedID- 22386936 | Statins have been shown to ameliorate renal function and reduce proteinuria in patients with chronic kidney disease. |
| PubMedID- 23497267 | Such studies have demonstrated associations of a resistive index to proteinuria in patients with chronic kidney disease with and without diabetes mellitus; [30] to albuminuria and also a measure of aortic stiffness (brachial-ankle) in 150 patients with type 2 diabetes mellitus; [31] and in patients with hypertension, a modest increase in renal resistive index was associated with a greater adjusted relative risk of albuminuria [32]. |
| PubMedID- 25018979 | Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. |
| PubMedID- 20703230 | The principal means for reducing proteinuria in patients with chronic kidney disease are strong blockade of the renin-angiotensin system and strict regulation of blood pressure (bp). |
| PubMedID- 24843543 | Several smaller randomized trials have indicated that paricalcitol reduces proteinuria in patients with chronic kidney disease. |
| PubMedID- 24372810 | Background: angiotensin-converting enzyme inhibitors (aceis) are currently used to control proteinuria in dogs with chronic kidney disease. |
| PubMedID- 23585423 | Effect of enalapril on glomerular filtration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial. |
| PubMedID- 23644107 | Conclusion: syndrome differentiation-based tcm treatment in addition to basic treatments can produce satisfactory therapeutic effects on proteinuria in patients with chronic kidney disease by improving the clinical symptoms, reducing tcm symptom scores and proteinuria, and protecting the renal functions. |
| PubMedID- 23691273 | As glomerulosclerosis becomes more extensive, the gfr starts to decrease and nonselective proteinuria may result leading to chronic kidney disease and subsequently esrd [11–13]. |
| PubMedID- 22607020 | We investigated the relationship between cys-c and proteinuria in patients with chronic kidney disease. |
| PubMedID- 21852669 | Whether central measures of bp or vascular stiffness are associated with increased risk of proteinuria in patients with chronic kidney disease (ckd) is unknown. |
| PubMedID- 23552860 | We compared the therapeutic effects of fasudil on the spontaneously hypercholesterolemic (shc) rat, a model of chronic kidney disease (ckd) with proteinuria, with those of the angiotensin receptor blocker olmesartan (ol) by paying attention to the proteinuria and the macrophage phenotype. |
| PubMedID- 23882402 | Over the years, she developed chronic kidney disease due to bence jones proteinuria, anorexia, chronic anemia (requiring multiple blood transfusions), multiple electrolyte abnormalities and herpes zoster for which she remained on prophylaxis. |
| PubMedID- 22019331 | Background: vitamin d has shown efficacy in the reduction of proteinuria in patients with chronic kidney disease. |
| PubMedID- 21251050 | Hepatocyte growth factor (hgf) has the therapeutic potential to improve renal fibrosis and proteinuria in rodents with chronic kidney disease. |
| PubMedID- 20671225 | Conclusions: in chronic kidney disease patients with residual proteinuria despite combined angiotensin-converting enzyme inhibitor and angiotensin receptor blockade therapy, add-on fluvastatin does not affect urinary proteins, but further reduces serum lipids and is safe. |
| PubMedID- 23167771 | We evaluated the antiproteinuric effect of pct in non-dialysis chronic kidney disease (ckd) patients with proteinuria greater than 0.5 g/24 h persisting despite anti-ras therapy titrated to minimize proteinuria in the absence of adverse effects. |
| PubMedID- 22073844 | As a pleiotropic effect, paricalcitol reduces proteinuria in patients with chronic kidney disease stages 2-4. |
| PubMedID- 26587302 | His past medical history was otherwise notable for hypertension, type ii diabetes mellitus, atrial fibrillation, and chronic kidney disease with bence jones proteinuria (k-flc proteinuria of 691 mg/dl). |
| PubMedID- 25018969 | Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. |
| PubMedID- 22737779 | proteinuria among patients with chronic kidney disease: a performance measure for improving patient outcomes. |
| PubMedID- 23551149 | Results: ten family members had chronic kidney disease with late-onset gross proteinuria and a variable course of declining renal function, starting in the fourth decade of life. |
Page: 1